Reaction Phenotyping: Current Industry Efforts to Identify Enzymes Responsible for Metabolizing Drug Candidates

Reaction phenotyping studies to identify specific enzymes involved in the metabolism of drug candidates are increasingly important in drug discovery efforts. Experimental approaches used for CYP reaction phenotyping include incubations with cDNA expressed CYP enzyme systems and incubations containing specific CYP enzyme inhibitors. Since both types of experiments present specific advantages as well as known drawbacks, these studies are generally viewed as complementary approaches. Although glucuronidation pathways are also known to present potential drug–drug interaction issues as well as challenges related to their polymorphic expression, reaction phenotyping approaches for glucuronidation are generally limited to cDNA expressed systems due to lack of availability of specific UGT inhibitors. This article presents a limited review of current approaches to reaction phenotyping studies used within the pharmaceutical industry.

[1]  D. Greenblatt,et al.  Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. , 2001, The Journal of pharmacology and experimental therapeutics.

[2]  M. Manns,et al.  Polymorphic Gene Regulation and Interindividual Variation of UDP-glucuronosyltransferase Activity in Human Small Intestine* , 2000, The Journal of Biological Chemistry.

[3]  S. Ludtke,et al.  Mechanism of alamethicin insertion into lipid bilayers. , 1996, Biophysical journal.

[4]  A. D. Rodrigues,et al.  The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6). , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[5]  A. Boobis,et al.  Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. , 1990, British journal of clinical pharmacology.

[6]  Rodrigues Ad,et al.  The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6). , 1997 .

[7]  A. Parkinson An Overview of Current Cytochrome P450 Technology for Assessing the Safety and Efficacy of New Materials , 1996, Toxicologic pathology.

[8]  W. Trager,et al.  (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[9]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[10]  Tony K L Kiang,et al.  UDP-glucuronosyltransferases and clinical drug-drug interactions. , 2005, Pharmacology & therapeutics.

[11]  A. D. Rodrigues,et al.  Use of in vitro human metabolism studies in drug development. An industrial perspective. , 1994, Biochemical pharmacology.

[12]  David J Greenblatt,et al.  Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[13]  S. Wrighton,et al.  Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. , 2000, Pharmacogenetics.

[14]  E. Tanaka,et al.  Clinically important pharmacokinetic drug–drug interactions: role of cytochrome P450 enzymes , 1998, Journal of clinical pharmacy and therapeutics.

[15]  F. Gonzalez,et al.  Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[16]  C. Guillemette,et al.  The Impact of UGT1A8, UGT1A9, and UGT2B7 Genetic Polymorphisms on the Pharmacokinetic Profile of Mycophenolic Acid After a Single Oral Dose in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[17]  D. Mansuy,et al.  Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. , 1996, Biochemistry.

[18]  T Ishizaki,et al.  Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.

[19]  C. Adithan,et al.  The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. , 2007, Current clinical pharmacology.

[20]  J. Spence,et al.  Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition , 2000, Clinical pharmacokinetics.

[21]  K. Krausz,et al.  Monoclonal Antibodies and Multifunctional Cytochrome P450: Drug Metabolism as Paradigm , 2006, Journal of clinical pharmacology.

[22]  B. Wong,et al.  Complexities of glucuronidation affecting in vitro in vivo extrapolation. , 2002, Current drug metabolism.

[23]  S. Clarke,et al.  Characterization of the inhibition of P4501A2 by furafylline. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[24]  Y. Berger,et al.  Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[25]  A. Y. Lu,et al.  Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[26]  D. Williams,et al.  Dietary indole-3-carbinol inhibits FMO activity and the expression of flavin-containing monooxygenase form 1 in rat liver and intestine. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[27]  J. Leonard,et al.  Pharmacokinetic Interaction between Ritonavir and Indinavir in Healthy Volunteers , 1998, Antimicrobial Agents and Chemotherapy.

[28]  C. Guillemette Pharmacogenomics of human UDP-glucuronosyltransferase enzymes , 2003, The Pharmacogenomics Journal.

[29]  S. Wrighton,et al.  In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[30]  L. Richert,et al.  Optimal detergent activation of rat liver microsomal UDP-glucuronosyl transferases toward morphine and 1-naphthol: contribution to induction and latency studies. , 1992, Biochemical pharmacology.

[31]  A. Hsu,et al.  Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. , 1998, Clinical pharmacokinetics.

[32]  J B Houston,et al.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.

[33]  R. Obach,et al.  Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitor. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[34]  P. Lehman,et al.  Glucuronidation of all-trans-retinoic acid and 5,6-epoxy-all-trans-retinoic acid. Activation of rat liver microsomal UDP-glucuronosyltransferase activity by alamethicin. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[35]  J. Mandl,et al.  Evidence for the intraluminal positioning of p-nitrophenol UDP-glucuronosyltransferase activity in rat liver microsomal vesicles. , 1994, Archives of biochemistry and biophysics.

[36]  C. Jamis-Dow,et al.  Glucuronidation of 3′-Azido-3′-Deoxythymidine (Zidovudine) by Human Liver Microsomes: Relevance to Clinical Pharmacokinetic Interactions with Atovaquone, Fluconazole, Methadone, and Valproic Acid , 1998, Antimicrobial Agents and Chemotherapy.

[37]  S. Yamada,et al.  Monospecific antipeptide antibodies against human hepatic UDP-glucuronosyltransferase 1A subfamily (UGT1A) isoforms. , 2006, Drug metabolism and pharmacokinetics.

[38]  G. Tucker,et al.  Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[39]  H. Yamazaki,et al.  Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[40]  G. de Sousa,et al.  In vitro interaction between cyclosporin A and macrolide antibiotics. , 1993, British journal of clinical pharmacology.

[41]  F. Schmidt Meta-Analysis , 2008 .

[42]  A. D. Rodrigues,et al.  Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. , 1999, Biochemical pharmacology.

[43]  Rodrigues Ad,et al.  Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes , 1999 .

[44]  S. Higuchi,et al.  Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. , 1998, Therapeutic drug monitoring.

[45]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[46]  A. Rettie,et al.  Human Hepatic Flavin-Containing Monooxygenases 1 (FMO1) and 3 (FMO3) Developmental Expression , 2002, Pediatric Research.

[47]  A. D. Rodrigues,et al.  Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. , 2002, Current drug metabolism.